Lymphoma Treatment: Watch and Wait

The "Watch and Wait" or watchful waiting treatment is used on indolent (slow growing) cancers. It means that a doctor does not actively treat a patient but monitors the growth of the disease.

Why is this done? In some cases, cancer is caught in its very early stages, when it is less responsive to chemotherapy and radiation therapy. The watch and wait method is used to ensure that when treatment is started, it is effective.

If a patient is living comfortably and doesn’t experience any uncomfortable side effects from their cancer, then the watch and wait method is often the doctor’s first choice. During this time, the patient will undergo frequent medical tests to determine the stage of the disease.

Once the cancer evolves into a treatable stage, then other treatment options are pursued. This may involve chemotherapy, radiotherapy, immunotherapy, surgery, or a combination of these.

The benefits of the watch and wait method are proven. Studies have examined cases where this method is used and have found that it doesn’t decrease a patient’s chance of survival when used properly. In fact, it is often helpful. Since most cancer treatments are harmful to the body, waiting to administer them until they are the most effective reduces damage to the patient.

The watch and wait method is never used on aggressive cancers. It is rarely used on cancers in advanced stages, unless the tumors are extremely slow growing.

Related Reading

Photo by Bill Branson, NCI

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap